UNSPSC 51162605: Benproperine embonate

This classification denotes an antitussive agent with the molecular formula C23H16O6.2C21H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 370C8CB2K3, chemically known as piperidine, 1-(1-methyl-2-(2-(phenylmethyl)phenoxy)ethyl)-, 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylate) (2:1), but more generally known as benproperine embonate, which bears US NIH Compound Identifier 11979739.

European Medicines Agency schedules benproperine embonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05728MIG. Most nations, for tariff purposes, schedule benproperine embonate under HS 29333999. SMILES: CC(COC1CCCCC1CC2CCCCC2)N3CCCCC3.CC(COC1CCCCC1CC2CCCCC2)N3CCCCC3.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.

UNSPSC 51162605 Benproperine embonate is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, but recent state and local solicitations under this code do not actually procure benproperine embonate. Instead, the code tags broader pharmaceutical procurement — naloxone (an opioid antagonist), generic multi-source pharmaceuticals, and over-the-counter products — indicating a misalignment between the code's nominal scope and what state and local government buyers are actually purchasing. State and local issuers using this code span county health departments and multi-state cooperative purchasing alliances. Seminole County, Florida procures naloxone and drug deactivation systems through competitive bidding; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, manages statewide and multi-state pharmaceutical contracts that extend to participating jurisdictions including Oregon. Both solicitations emphasize compliance with pharmaceutical manufacturing standards (current Good Manufacturing Practices and the Drug Supply Chain Security Act), established wholesaler relationships, and fixed or competitive pricing structures.

Recent activity appears concentrated in Florida and the Upper Midwest, with Seminole County posting an IFB on June 30, 2026, for 1,900 units of naloxone and 800 drug deactivation systems annually (due July 26, 2023) for quarterly delivery to the Seminole County Community Health Building in Sanford, and MMCAP posting an RFP on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products (proposals due March 26, 2026, with contract effectiveness July 1, 2026). The Seminole County procurement requires drug-free workplace and E-Verify certification, carries a two-year initial term with one-year renewal option, and notes potential FEMA funding. The MMCAP RFP mandates vendor relationships with at least two of three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), cGMP and DSCSA certification, $5,000,000 commercial general liability coverage, and a 3 percent administrative fee on all purchases. Neither solicitation names explicit set-aside or disadvantaged-business designations.